239802

Curcumin, Curcuma longa L.

A cell-permeable and irreversible antitumor and anti-inflammatory agent that acts as an inhibitor of 5-lipoxygenase (IC₅₀ = 8 µM) and cyclooxygenase (IC₅₀ = 52 µM).

• Sinónimos: Curcumin, Curcuma longa L., 1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione, NOD2 Signaling Inhibitor I, Nucleotide-binding Oligomerization Domain 2 Signaling Inhibitor I, Histone Acetyltransferase Inhibitor I, HAT Inhibitor I, p300/CBP Inhibitor I
• Fórmula empírica (notación de Hill): C₂₁H₂₀O₆
• Número de CAS: 458-37-7
• Peso molecular: 368.38
• Número MDL: MFCD00008365
• Código UNSPSC: 12352205
• NACRES: NA.77

Propiedades

• Nivel de calidad: 100
• Análisis: ≥80% (HPLC)
• formulario: solid
• fabricante / nombre comercial: Calbiochem^®
• condiciones de almacenamiento: OK to freeze; protect from light
• color: orange-yellow
• solubilidad: acetic acid: 10 mg/mL; DMSO: 5 mg/mL
• Condiciones de envío: ambient
• temp. de almacenamiento: 10-30°C
• InChI: 1S/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-13,22,24-25H,1-2H3/b7-3+,8-4+,16-13-
• Clave InChI: ZIUSSTSXXLLKKK-KOBPDPAPSA-N

Descripción

Descripción general

A cell permeable antitumor and anti-inflammatory agent that acts as an inhibitor of 5-lipoxygenase (IC₅₀ = 8 µM) and cyclooxygenase (IC₅₀ = 52 µM). Confers significant protection against neurotoxic and genotoxic agents. Also inhibits the induction of nitric oxide synthase in activated macrophages (IC₅₀ = 6 µM). Recently shown to inhibit the EGF receptor intrinsic kinase activity in the human epidermoid carcinoma A431 cells in a dose- and time-dependent manner. Also shown to be a p300/CREB-binding protein-specific inhibitor of histone acetyltransferase, inhibiting the acetylation of histones H3 and H4 with an

IC₅₀ of ~25 µM. Does not affect p300/CREB binding protein-associated factor (PCAF).

A cell-permeable and irreversible antitumor and anti-inflammatory agent that acts as an inhibitor of 5-lipoxygenase (IC₅₀ = 8 µM) and cyclooxygenase (IC₅₀ = 52 µM). Confers significant protection against neurotoxic and genotoxic agents. Also inhibits the induction of nitric oxide synthase in activated macrophages (IC₅₀ = 6 µM). Recently shown to inhibit the EGF receptor intrinsic kinase activity in the human epidermoid carcinoma A431 cells in a dose- and time-dependent manner. Also shown to be a p300/CREB-binding protein-specific inhibitor of histone acetyltransferase, inhibiting the acetylation of histones H3 and H4 with an IC₅₀ of ~25 µM. Does not affect p300/CREB binding protein-associated factor (PCAF).

Acciones bioquímicas o fisiológicas

Cell permeable: yes

Primary Target
5-lipoxygenase

Product does not compete with ATP.

Reversible: no

Target IC₅₀: 8 µM, 52 µM, against 5-lipoxygenase, Cyclooxygenase, respectively; 6 µM inhibiting the induction of nitric oxide synthase in activated macrophages

Advertencia

Toxicity: Standard Handling (A)

Reconstitución

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Otras notas

Hung, S., et al. 2008. Mol. Pharmacol.74, 274.
Cui, L., et al. 2007. Antimicrob. Agents Chemother.51, 488.
Salvioli, S., et al. 2007. eCAM4, 181.
Balasubramanyam, K. et al. 2004. J. Biol. Chem.279, 51163.
Brouet, I., and Okshima, H. 1995. Biochem. Biophys. Res. Commun. 206, 533.
Korutla, L., and Kumar, R. 1994. Biochim. Biophys. Acta1224, 597.
Flynn, D.L., et al. 1986. Prostagland. Leuk. Med. 22, 357.

Información legal

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Información de seguridad

• Código de clase de almacenamiento: 11 - Combustible Solids
• Clase de riesgo para el agua (WGK): WGK 3
• Punto de inflamabilidad (°F): Not applicable
• Punto de inflamabilidad (°C): Not applicable